449 related articles for article (PubMed ID: 26318293)
21. Systemic Immune Dysfunction in Cancer Patients Driven by IL6 Induction of LAG3 in Peripheral CD8+ T Cells.
Somasundaram A; Cillo AR; Lampenfeld C; Workman CJ; Kunning S; Oliveri L; Velez M; Joyce S; Calderon M; Dadey R; Rajasundaram D; Normolle DP; Watkins SC; Herman JG; Kirkwood JM; Lipson EJ; Ferris RL; Bruno TC; Vignali DAA
Cancer Immunol Res; 2022 Jul; 10(7):885-899. PubMed ID: 35587532
[TBL] [Abstract][Full Text] [Related]
22. Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3.
Lauder SN; Smart K; Kersemans V; Allen D; Scott J; Pires A; Milutinovic S; Somerville M; Smart S; Kinchesh P; Lopez-Guadamillas E; Hughes E; Jones E; Scurr M; Godkin A; Friedman LS; Vanhaesebroeck B; Gallimore A
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33093155
[TBL] [Abstract][Full Text] [Related]
23. Function and regulation of LAG3 on CD4
Ma QY; Huang DY; Zhang HJ; Wang S; Chen XF
Exp Cell Res; 2017 Nov; 360(2):358-364. PubMed ID: 28935468
[TBL] [Abstract][Full Text] [Related]
24. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.
Matsuzaki J; Gnjatic S; Mhawech-Fauceglia P; Beck A; Miller A; Tsuji T; Eppolito C; Qian F; Lele S; Shrikant P; Old LJ; Odunsi K
Proc Natl Acad Sci U S A; 2010 Apr; 107(17):7875-80. PubMed ID: 20385810
[TBL] [Abstract][Full Text] [Related]
25. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
26. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
27. Roles, function and relevance of LAG3 in HIV infection.
Graydon CG; Balasko AL; Fowke KR
PLoS Pathog; 2019 Jan; 15(1):e1007429. PubMed ID: 30653605
[TBL] [Abstract][Full Text] [Related]
28. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
[TBL] [Abstract][Full Text] [Related]
29. TOX promotes the exhaustion of antitumor CD8
Wang X; He Q; Shen H; Xia A; Tian W; Yu W; Sun B
J Hepatol; 2019 Oct; 71(4):731-741. PubMed ID: 31173813
[TBL] [Abstract][Full Text] [Related]
30. Functional Exhaustion of HBV-Specific CD8 T Cells Impedes PD-L1 Blockade Efficacy in Chronic HBV Infection.
Ferrando-Martinez S; Snell Bennett A; Lino E; Gehring AJ; Feld J; Janssen HLA; Robbins SH
Front Immunol; 2021; 12():648420. PubMed ID: 34589081
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models.
Leone RD; Sun IM; Oh MH; Sun IH; Wen J; Englert J; Powell JD
Cancer Immunol Immunother; 2018 Aug; 67(8):1271-1284. PubMed ID: 29923026
[TBL] [Abstract][Full Text] [Related]
32. Beyond Type 1 Regulatory T Cells: Co-expression of LAG3 and CD49b in IL-10-Producing T Cell Lineages.
Huang W; Solouki S; Carter C; Zheng SG; August A
Front Immunol; 2018; 9():2625. PubMed ID: 30510554
[TBL] [Abstract][Full Text] [Related]
33. Effects of immune checkpoint blockade on antigen-specific CD8
Ogando-Rivas E; Castillo P; Jones N; Trivedi V; Drake J; Dechkovskaia A; Candelario KM; Yang C; Mitchell DA
Microbiol Immunol; 2022 May; 66(5):201-211. PubMed ID: 35150167
[TBL] [Abstract][Full Text] [Related]
34. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
Front Immunol; 2018; 9():1955. PubMed ID: 30214445
[No Abstract] [Full Text] [Related]
35. Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor.
Ruffo E; Wu RC; Bruno TC; Workman CJ; Vignali DAA
Semin Immunol; 2019 Apr; 42():101305. PubMed ID: 31604537
[TBL] [Abstract][Full Text] [Related]
36. Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC
Zhang J; Larrocha PS; Zhang B; Wainwright D; Dhar P; Wu JD
J Immunother Cancer; 2019 Aug; 7(1):223. PubMed ID: 31446896
[TBL] [Abstract][Full Text] [Related]
37. CD8 + T Cells Exhibit an Exhausted Phenotype in Hemophagocytic Lymphohistiocytosis.
Kelkar MG; Bargir UA; Malik-Yadav R; Gupta M; Dalvi A; Jodhawat N; Shinde S; Madkaikar MR
J Clin Immunol; 2021 Nov; 41(8):1794-1803. PubMed ID: 34389889
[TBL] [Abstract][Full Text] [Related]
38. Multiplex Immuno-Liquid Chromatography-Mass Spectrometry-Parallel Reaction Monitoring (LC-MS-PRM) Quantitation of CD8A, CD4, LAG3, PD1, PD-L1, and PD-L2 in Frozen Human Tissues.
Zhang Q; Salzler R; Dore A; Yang J; Ma D; Olson WC; Liu Y
J Proteome Res; 2018 Nov; 17(11):3932-3940. PubMed ID: 30277784
[TBL] [Abstract][Full Text] [Related]
39. Interleukin-35 Limits Anti-Tumor Immunity.
Turnis ME; Sawant DV; Szymczak-Workman AL; Andrews LP; Delgoffe GM; Yano H; Beres AJ; Vogel P; Workman CJ; Vignali DA
Immunity; 2016 Feb; 44(2):316-29. PubMed ID: 26872697
[TBL] [Abstract][Full Text] [Related]
40. Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression.
Hossain DMS; Javaid S; Cai M; Zhang C; Sawant A; Hinton M; Sathe M; Grein J; Blumenschein W; Pinheiro EM; Chackerian A
J Clin Invest; 2018 Feb; 128(2):644-654. PubMed ID: 29337311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]